Amphivena Therapeutics was established in 2013 out of San Francisco, California. The CEO and President, JeanMarie Guenot – since her tenure – has managed to lead the company to great pharmaceutical and therapeutic development success. She is a great leader with over 20 years of experience in pharmaceuticals and biotechnology, which has brought her not only resolution in her field, but commendable awards.
JeanMarie Guenot, before starting with Amphivena Therapuetics, became the founder of an ophthalmic company (incubator related) called SKS Ocular, which specialties included the following, but not limited to: ocular inflammation and therapeutics for glaucoma. She would also become the vice president of corporate at PDL Biopharma. There, she would successfully lead the R&D department and commercial product portfolios. Her work history is quite lengthy. A more detailed account is available through Businesswire.com.
Since she became President and CEO of Amphivena Therapeutics, she has helped the firm grow tremendously. The firm at https://www.linkedin.com/in/jeanmarie-guenot-4a140617, over the years, has managed to develop numerous solutions directed at eradicating cancerous cells. These solutions have managed to be the hero of many cancer patients.
Throughout her career, Guenot has had the pleasure of earning a couple of prestigious awards. In 2005, she earned the “Bio Business Networks Innovative Bio Partner” award. And in 2006, she earned herself the “Licensing Executives Societies Deal of Distinction” award. Two great accomplishments that were not easy to come by and well deserved.
She is a very important figure when it comes to the progress that has guided her industry to cancer combat solutions. You can find her on social media sites as well, sites such as Crunchbase, where a timeline of her progress is available and Linkedin, where her work history is accessible.
JeanMarie Guenot’s career as President and CEO of Amphivena Therapeutics has been well deserved. With her leadership, the firm has made much progress and with her background, it is safe to predict continuous pharmaceutical success. As her firm manufactures drugs and treatments for cancer, JeanMarie’s dedication to pharmaceuticals since her start will continue to influence the world of tomorrow.